Skip to main content
. 2022 Mar 14;11(6):986. doi: 10.3390/cells11060986

Table 1.

Anti-ErbB/ligand approaches in preclinical models of lung fibrosis.

Targeted
Molecule		 Inhibitor/
Antibody		 Animal Model Outcome Reference
ErbB1 AG1478 Vanadium
pentoxide		 Favorable Rice et al., 1999 [73]
ErbB1 Gefitinib Bleomycin Favorable Ishii et al., 2006 [75];
Wang et al., 2010 [74]
ErbB1 Gefitinib Bleomycin Harmful Suzuki et al., 2003 [76]
ErbB1 Gefitinib rtTA-CCSP 4-TGF-α 5 Favorable Hardie et al. 2004 [88]
PI3K 1 PX-866 rtTA-CCSP-TGF-α Favorable Hardie et al., 2010 [92]
MEK 2 ARRY-142886 rtTA-CCSP-TGF-α Favorable Madala et al., 2012 [93]
AREG 3 AREG siRNA dox-CC10 6-TGF-β1 7 Favorable Zhou et al., 2012 [94]
ErbB1 AG1478 dox-CC10-TGF-β1 Favorable Zhou et al., 2012 [94]
ErbB1/2 Lapatinib Bleomycin Favorable Andrianifahanana et al., 2013 [96]
ErbB2 anti-ErbB2 antibody (2C4) Bleomycin Favorable Faress et al., 2007 [109]

1 PI3K, phosphoinositide 3-kinase; 2 MEK, mitogen-activated protein kinase; 3 AREG, amphiregulin; 4 rtTA-CCSP, tetracycline-inducible Clara cell secretory protein; 5 TGF-α, transforming growth factor α; 6 dox-CC10, doxycycline-regulatable Clara cell 10-kDa protein; 7 TGF-β, transforming growth factor β1.